Genmab: shares slightly up after broker raises target
(CercleFinance.com) - Genmab shares are inching up 0.
1% at 1,191 Danish kronor on Monday after Barclays raised its target price for the Danish biotechnology firm's share.
This morning Barclays - which has an "overweight" rating on the share - raised its target price from 1,200 Danish kronor to 1,300 Danish kronor as part of a research note on the European pharmaceuticals industry.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
1% at 1,191 Danish kronor on Monday after Barclays raised its target price for the Danish biotechnology firm's share.
This morning Barclays - which has an "overweight" rating on the share - raised its target price from 1,200 Danish kronor to 1,300 Danish kronor as part of a research note on the European pharmaceuticals industry.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.